drugset

drugset / Trial / NCT07110584

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

NCT07110584 ↗

Phase 1/2 Recruiting 235 enrolled ModeX Therapeutics, An OPKO Health Company

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.

Timeline

Start: 2025-10-01
Primary completion: 2031-06-30
Completion: 2031-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MDX2004	Unknown	—	Intravenous

Indications